We are live on ! Find out more
FBRX icon

Forte Biosciences

58 hedge funds and large institutions have $4.38M invested in Forte Biosciences in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $363K | Put options by funds: $156K

0.02% less ownership

Funds ownership: 0.09%0.07% (-0.02%)

22% less funds holding

Funds holding: 7458 (-16)

30% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 20

71% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 21

92% less capital invested

Capital invested by funds: $56.4M → $4.38M (-$52M)

Holders
58
Holders Change
-16
Holders Change %
-21.62%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
14
Reduced
20
Closed
21
Calls
$363K
Puts
$156K
Net Calls
+$207K
Net Calls Change
+$146K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$1.07M -$252K -166 -4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$665K -$258K -170 -6%
State Street
3
State Street
Massachusetts
$375K +$897K +591 +64%
ICM
4
ISZO Capital Management
New York
$375K +$2.29M +1,509 New
Renaissance Technologies
5
Renaissance Technologies
New York
$256K +$1.44M +952 +1,221%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$192K -$1.52K -1 -0.1%
Northern Trust
7
Northern Trust
Illinois
$177K +$138K +91 +15%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$157K +$592K +390 +158%
Deutsche Bank
9
Deutsche Bank
Germany
$105K -$378K -249 -37%
N
10
Nuveen
North Carolina
$80K +$98.7K +65 +25%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$76K +$364K +240 +364%
JP Morgan Chase
12
JP Morgan Chase
New York
$73K -$1.49M -979 -77%
CM
13
Caption Management
Oklahoma
$64K -$127K -84 -25%
Citadel Advisors
14
Citadel Advisors
Florida
$51K -$111K -73 -26%
BCM
15
Bridgeway Capital Management
Texas
$46K -$129K -85 -31%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$42K +$188K +124 +270%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$41K -$48.6K -32 -16%
LPL Financial
18
LPL Financial
California
$41K +$16.7K +11 +7%
Two Sigma Investments
19
Two Sigma Investments
New York
$41K +$250K +165 New
Charles Schwab
20
Charles Schwab
California
$34K
BF
21
Blankinship & Foster
California
$27K
CG
22
Colony Group
Massachusetts
$25K
Millennium Management
23
Millennium Management
New York
$23K -$33.4K -22 -19%
Wells Fargo
24
Wells Fargo
California
$22K -$83.5K -55 -38%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$21K -$126K -83 -49%

FBRX Hedge Fund Activity: Q3 2019 in Review

58 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2019, worth a combined $4.38M — down 92% from $56.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of FBRX and 6 opened new positions — a net loss of 15 holders — while 20 trimmed existing stakes and 14 added.

The largest buyer was ISZO Capital Management, opening a new position worth an estimated $2.29M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.48M sold.

  • 58 institutional investors held Forte Biosciences (FBRX) as of Q3 2019, down from 74 in Q2 2019.
  • Funds reported $4.38M of Forte Biosciences stock for Q3 2019, down 92% quarter-over-quarter.
  • 6 funds opened new Forte Biosciences positions in Q3 2019 and 21 closed out, a net change of -15 holders.
  • The largest Forte Biosciences buyer in Q3 2019 was ISZO Capital Management, an estimated $2.29M added.
  • The largest Forte Biosciences seller in Q3 2019 was Sectoral Asset Management, an estimated $4.48M sold.

Based on aggregated 13F filings for Q3 2019.